Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
about
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionRole of ROS and RNS Sources in Physiological and Pathological ConditionsClofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodentsInduction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liverClofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs.A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.Effects of PPARα inhibition in head and neck paraganglioma cellsA natural propenoic acid derivative activates peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).PPARalpha: energy combustion, hypolipidemia, inflammation and cancerAnalysis of eight oil spill dispersants using rapid, in vitro tests for endocrine and other biological activityThe Role of PPARα Activation in Liver and Muscle.Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed ratsEffects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.Caspase 2 activation and ER stress drive rapid Jurkat cell apoptosis by clofibrateDifferential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesisInhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.Tetradecylthioacetic acid increases hepatic mitochondrial β-oxidation and alters fatty acid composition in a mouse model of chronic inflammationSuccessful drug development despite adverse preclinical findings part 2: examples.Effect of a Large Dose of Di (2-ethylhexyl) phthalate (DEHP) on Hepatic Peroxisome in Cynomolgus Monkeys (Macaca Fascicularis).Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growthThe truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genesSustained formation of alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-alpha, but not NADPH oxidase.Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferationModulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor alpha.Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors.Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expressionThe toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver.Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolismPPARalpha- and DEHP-Induced CancersArachidonic and oleic acid exert distinct effects on the DNA methylome.Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liverMechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.
P2860
Q24601222-94C9DF08-FE4D-46B2-9914-3E59E49A1B28Q26740342-0ED76562-3233-4C74-9F90-B5213AB8373EQ28222350-07CA9517-7865-4D3C-86C3-99E9099F9A64Q28585920-46C7D58E-4042-457B-9A62-0AABE03092DFQ30319871-A501D4C1-92B4-41BF-98EC-ACDB5F695825Q33569334-7AD03156-3BFD-4193-8921-DFE8DC10BF3BQ33625872-1FB4ABFC-780F-4B9F-AA88-87041C75F8A8Q33779008-3ED12164-426E-405D-AC4B-EDF4ABEA4788Q33791840-DDF23DF7-3DF9-418E-AB84-07CB9EDD6BACQ33805104-7676F5D3-50D0-4C3C-8CAB-4E07F6281129Q34092950-CF60BE37-E22E-412C-BBEC-BA2209EFBC1EQ34106233-0B40F813-A83E-4F91-8390-A0706E01DB38Q34149881-3A370F74-0929-4221-896C-92820547479DQ34189111-B8751D3A-887A-41C9-885F-F4DB6FFDFA5FQ34428761-FC1172A7-A36B-4EEF-BE3F-BA8F28352F87Q34565215-CEFD5867-A18E-4F19-B158-74361D377E2DQ34948760-E7DDE680-F2E0-4A9D-B4B7-8F56A21E4538Q35079707-61C11C27-50C8-4689-A3A4-863488418E11Q35091569-32158916-6C4C-4840-8C6F-B2FC7DE3BE32Q35603965-F0B05E7A-D6CB-4114-9876-6DE01402A701Q35603991-31D6927D-E634-4C0E-BC5C-990F1D7C7E48Q35613331-C85592F8-F347-47E7-B712-4600F60E2BD8Q35671904-C4DC87A4-82E4-428D-82EA-BC6619B8FF70Q35677612-E7844FBB-B2D3-4EF8-8C27-1A7733EE2533Q35691236-6780E819-DCAA-415D-BA20-1D37A428C4DAQ35857112-DA0550BB-2958-4979-B017-60EEEA49A718Q35961671-27FDAE80-136C-4214-B09D-2B8C4FA02E4DQ36157386-D380B059-0461-4470-9E3C-4BF44C11B8B1Q36202782-11FCA712-729C-45FD-B8E7-0427957D56D3Q36294936-6C73327C-D3B7-4E3F-BE1E-FA00D4ED1189Q36298157-55029263-2065-461A-B0FA-814EF6B94B83Q36328530-E1363FD9-925C-4900-9172-ACB515061CBCQ36378309-2CCA207C-89B2-440C-AB48-8AF57A228B0CQ36586072-6DEA6A51-B22C-4DD3-90CE-2D9287FBA2E8Q36781253-9C79B2A5-67C2-4371-BF42-10148CC250F2Q36857053-5BEF67B4-1F26-40FB-AE3B-8345D0682024Q36956881-9DD4B6A4-C649-44B5-9DAD-B88A5DAF4EE0Q37114391-5A3C16E7-FEBA-4093-AD10-719F0150F8C7Q37125240-57CAE6C9-57FD-417C-9B2D-6872180F8EE0Q37152858-9659A5F6-9EB1-47F8-B255-E5547FA89AED
P2860
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@ast
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@en
type
label
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@ast
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@en
prefLabel
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@ast
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@en
P2093
P1476
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
@en
P2093
Connie Cheung
Frank J Gonzalez
Jeffrey M Peters
P2888
P304
P356
10.1007/S00109-005-0678-9
P577
2005-06-23T00:00:00Z